Interferons (IFNs) suppress viral infection through the induction of >400 interferon-stimulated genes (ISGs). Among ISGs, IFN-induced protein with tetratricopeptide repeats (IFITs) is one of the most potent and well-characterized ISGs. IFIT family consists of 4 cluster genes. It has been suggested that the antiviral action of each IFIT employs distinct mechanisms. In addition, it has been shown that each IFIT exhibits its antiviral properties partially in a pathogen-specific manner. To date, the expression profile of IFITs in the liver, as well as the antiviral potency of the individual IFITs in the regulation of hepatitis C virus (HCV) infection, is not yet fully defined. Our previous study found that the expression of hepatic IFITs is well correlated with the outcome of IFN-based antiviral therapy. This study explored the significance of each IFIT in the suppression of HCV. Our in vitro and in vivo studies with humanized liver chimeric mouse system revealed that IFIT1, 2, and 3/4 play an important role in the suppression of HCV. In addition, our in vitro experiment found that all IFITs possess a comparable anti-HCV potency. Follow-up studies collectively indicated that IFITs suppress HCV likely through 2 distinct mechanisms: (1) inhibition of internal ribosome entry site-dependent viral protein translation initiation complex according to experiments with bicistronic reporter assay as well as confocal microscopic analyses and (2) sequestration of viral genome based on an experiment using replication defective viral genome. In conclusion, our study defined the importance of IFITs in the regulation of HCV and also suggested the multifaceted antiviral actions.
Get full access to this article
View all access options for this article.
References
1.
AbbasYM, PichlmairA, GornaMW, Superti-FurgaG, NagarB. 2013. Structural basis for viral 5'-PPP-RNA recognition by human IFIT proteins. Nature, 494(7435):60–64.
2.
AghemoA, De FrancescoR. 2013. New horizons in hepatitis C antiviral therapy with direct-acting antivirals. Hepatology, 58(1):428–438.
3.
BangBR, ElmasryS, SaitoT. 2016. Organ system view of the hepatic innate immunity in HCV infection. J Med Virol, 88(12):2025–2037.
4.
BaumertTF, FauvelleC, ChenDY, LauerGM. 2014. A prophylactic hepatitis C virus vaccine: a distant peak still worth climbing. J Hepatol, 61(1 Suppl):S34–S44.
5.
ConsortiumEP. 2012. An integrated encyclopedia of DNA elements in the human genome. Nature, 489(7414):57–74.
6.
DaffisS, SzretterKJ, SchriewerJ, LiJ, YounS, ErrettJ, LinTY, SchnellerS, ZustR, DongH, ThielV, SenGC, FensterlV, KlimstraWB, PiersonTC, BullerRM, GaleMJr., ShiPY, DiamondMS. 2010. 2'-O methylation of the viral mRNA cap evades host restriction by IFIT family members. Nature, 468(7322):452–456.
7.
DiamondMS, FarzanM. 2013. The broad-spectrum antiviral functions of IFIT and IFITM proteins. Nat Rev Immunol, 13(1):46–57.
8.
ElmasryS, WadhwaS, BangBR, CookL, ChopraS, KanelG, KimB, HarperT, FengZ, JeromeKR, KahnJ, SaitoT. 2016. Detection of occult hepatitis C virus infection in patients who achieved a sustained virologic response to direct-acting antiviral agents for recurrent infection after liver transplantation. Gastroenterology, 152(3):550–553.
FensterlV, SenGC. 2015. Interferon-induced Ifit proteins: their role in viral pathogenesis. J Virol, 89(5):2462–2468.
11.
FoyE, LiK, SumpterR, LooYM, JohnsonCL, WangCF, FishPM, YoneyamaM, FujitaT, LemonSM, GaleM. 2005. Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling. Proc Natl Acad Sci U S A, 102(8):2986–2991.
12.
FoyE, LiK, WangCF, SumpterR, IkedaM, LemonSM, GaleM. 2003. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science, 300(5622):1145–1148.
13.
GaleMJr., KwieciszewskiB, DossettM, NakaoH, KatzeMG. 1999. Antiapoptotic and oncogenic potentials of hepatitis C virus are linked to interferon resistance by viral repression of the PKR protein kinase. J Virol, 73(8):6506–6516.
GrandvauxN, ServantMJ, tenOeverB, SenGC, BalachandranS, BarberGN, LinR, HiscottJ. 2002. Transcriptional profiling of interferon regulatory factor 3 target genes: direct involvement in the regulation of interferon-stimulated genes. J Virol, 76(11):5532–5539.
16.
GreenDS, YoungHA, ValenciaJC. 2017. Current prospects of type II interferon gamma signaling and autoimmunity. J Biol Chem, 292(34):13925–13933.
17.
HiragaN, AbeH, ImamuraM, TsugeM, TakahashiS, HayesCN, OchiH, TatenoC, YoshizatoK, NakamuraY, KamataniN, ChayamaK. 2011. Impact of viral amino acid substitutions and host interleukin-28b polymorphism on replication and susceptibility to interferon of hepatitis C virus. Hepatology, 54(3):764–771.
18.
HondaM, SakaiA, YamashitaT, NakamotoY, MizukoshiE, SakaiY, NakamuraM, ShirasakiT, HorimotoK, TanakaY, TokunagaK, MizokamiM, KanekoS. 2010. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology, 139(2):499–509.
19.
HornerSM, ParkHS, GaleMJr. 2012. Control of innate immune signaling and membrane targeting by the Hepatitis C virus NS3/4A protease are governed by the NS3 helix alpha0. J Virol, 86(6):3112–3120.
20.
IkedaM, SugiyamaK, MizutaniT, TanakaT, TanakaK, SekiharaH, ShimotohnoK, KatoN. 1998. Human hepatocyte clonal cell lines that support persistent replication of hepatitis C virus. Virus Res, 56(2):157–167.
21.
ImprotaT, PineR, PfefferLM. 1992. Interferon-gamma potentiates the antiviral activity and the expression of interferon-stimulated genes induced by interferon-alpha in U937 cells. J Interferon Res, 12(2):87–94.
22.
InoueK, UmeharaT, RueggUT, YasuiF, WatanabeT, YasudaH, DumontJM, ScalfaroP, YoshibaM, KoharaM. 2007. Evaluation of a cyclophilin inhibitor in hepatitis C virus-infected chimeric mice in vivo. Hepatology, 45(4):921–928.
23.
IshidaY, YamasakiC, YanagiA, YoshizaneY, FujikawaK, WatashiK, AbeH, WakitaT, HayesCN, ChayamaK, TatenoC. 2015. Novel robust in vitro hepatitis B virus infection model using fresh human hepatocytes isolated from humanized mice. Am J Pathol, 185(5):1275–1285.
24.
JohnsonB, VanBlarganLA, XuW, WhiteJP, ShanC, ShiPY, ZhangR, AdhikariJ, GrossML, LeungDW, DiamondMS, AmarasingheGK. 2018. Human IFIT3 modulates IFIT1 RNA binding specificity and protein stability. Immunity, 48(3):487–499 e5.
25.
KatibahGE, QinY, SidoteDJ, YaoJ, LambowitzAM, CollinsK. 2014. Broad and adaptable RNA structure recognition by the human interferon-induced tetratricopeptide repeat protein IFIT5. Proc Natl Acad Sci U S A, 111(33):12025–12030.
26.
KatoT, DateT, MurayamaA, MorikawaK, AkazawaD, WakitaT. 2006. Cell culture and infection system for hepatitis C virus. Nat Protoc, 1(5):2334–2339.
27.
KatzeMG, HeY, GaleMJr. 2002. Viruses and interferon: a fight for supremacy. Nat Rev Immunol, 2(9):675–687.
28.
KokordelisP, KramerB, KornerC, BoeseckeC, VoigtE, IngilizP, GlassnerA, EisenhardtM, WolterF, KaczmarekD, NischalkeHD, RockstrohJK, SpenglerU, NattermannJ. 2014. An effective interferon-gamma-mediated inhibition of hepatitis C virus replication by natural killer cells is associated with spontaneous clearance of acute hepatitis C in human immunodeficiency virus-positive patients. Hepatology, 59(3):814–827.
29.
LanfordRE, GuerraB, BiggerCB, LeeH, ChavezD, BraskyKM. 2007. Lack of response to exogenous interferon-alpha in the liver of chimpanzees chronically infected with hepatitis C virus. Hepatology, 46(4):999–1008.
30.
LauDTY, NegashA, ChenJ, CrochetN, SinhaM, ZhangY, GuedjJ, HolderS, SaitoT, LemonSM, LuxonBA, PerelsonAS, GaleMJr. 2013. Innate immune tolerance and the role of Kupffer cells in differential responses to interferon therapy among patients with HCV genotype 1 infection. Gastroenterology, 144(2):402–413.e12.
31.
LauerGM, KimAY. 2006. Spontaneous resolution of chronic hepatitis C virus infection: are we missing something?. Clin Infect Dis, 42(7):953–954.
32.
LevyDE, LewDJ, DeckerT, KesslerDS, DarnellJEJr. 1990. Synergistic interaction between interferon-alpha and interferon-gamma through induced synthesis of one subunit of the transcription factor ISGF3. EMBO J, 9(4):1105–1111.
33.
LiangTJ, WardJW. 2018. Hepatitis C in injection-drug users—a hidden danger of the opioid epidemic. N Engl J Med, 378(13):1169–1171.
34.
LiangY, IshidaH, LenzO, LinTI, NyanguileO, SimmenK, PylesRB, BourneN, YiM, LiK, LemonSM. 2008. Antiviral suppression vs restoration of RIG-I signaling by hepatitis C protease and polymerase inhibitors. Gastroenterology, 135(5):1710–1718 e2.
35.
LiuXY, ChenW, WeiB, ShanYF, WangC. 2011. IFN-induced TPR protein IFIT3 potentiates antiviral signaling by bridging MAVS and TBK1. J Immunol, 187(5):2559–2568.
36.
LooYM, FornekJ, CrochetN, BajwaG, PerwitasariO, Martinez-SobridoL, AkiraS, GillMA, Garcia-SastreA, KatzeMG, GaleMJr. 2008. Distinct RIG-I and MDA5 signaling by RNA viruses in innate immunity. J Virol, 82(1):335–345.
McFarlandAP, HornerSM, JarretA, JoslynRC, BindewaldE, ShapiroBA, DelkerDA, HagedornCH, CarringtonM, GaleMJr., SavanR. 2014. The favorable IFNL3 genotype escapes mRNA decay mediated by AU-rich elements and hepatitis C virus-induced microRNAs. Nat Immunol, 15(1):72–79.
39.
NeumannAU, LamNP, DahariH, GretchDR, WileyTE, LaydenTJ, PerelsonAS. 1998. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science, 282(5386):103–107.
40.
O'BrienTR, Prokunina-OlssonL, DonnellyRP. 2014. IFN-lambda4: the paradoxical new member of the interferon lambda family. J Interferon Cytokine Res, 34(11):829–838.
41.
OoiEL, ChanST, ChoNE, WilkinsC, WoodwardJ, LiM, KikkawaU, TellinghuisenT, GaleMJr., SaitoT. 2014. Novel antiviral host factor, TNK1, regulates IFN signaling through serine phosphorylation of STAT1. Proc Natl Acad Sci U S A, 111(5):1909–1914.
42.
PichlmairA, LassnigC, EberleCA, GornaMW, BaumannCL, BurkardTR, BurckstummerT, StefanovicA, KriegerS, BennettKL, RulickeT, WeberF, ColingeJ, MullerM, Superti-FurgaG. 2011. IFIT1 is an antiviral protein that recognizes 5'-triphosphate RNA. Nat Immunol, 12(7):624–630.
43.
Prokunina-OlssonL, MuchmoreB, TangW, PfeifferRM, ParkH, DickensheetsH, HergottD, Porter-GillP, MumyA, KohaarI, ChenS, BrandN, TarwayM, LiuL, SheikhF, AstemborskiJ, BonkovskyHL, EdlinBR, HowellCD, MorganTR, ThomasDL, RehermannB, DonnellyRP, O'BrienTR. 2013. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet, 45(2):164–171.
44.
QiaoY, GiannopoulouEG, ChanCH, ParkSH, GongS, ChenJ, HuX, ElementoO, IvashkivLB. 2013. Synergistic activation of inflammatory cytokine genes by interferon-gamma-induced chromatin remodeling and toll-like receptor signaling. Immunity, 39(3):454–469.
45.
RaghuramanS, ParkH, OsburnWO, WinkelsteinE, EdlinBR, RehermannB. 2012. Spontaneous clearance of chronic hepatitis C virus infection is associated with appearance of neutralizing antibodies and reversal of T-cell exhaustion. J Infect Dis, 205(5):763–771.
46.
RaychoudhuriA, ShrivastavaS, SteeleR, KimH, RayR, RayRB. 2011. ISG56 and IFITM1 proteins inhibit hepatitis C virus replication. J Virol, 85(24):12881–12889.
47.
RobertsonG, HirstM, BainbridgeM, BilenkyM, ZhaoY, ZengT, EuskirchenG, BernierB, VarholR, DelaneyA, ThiessenN, GriffithOL, HeA, MarraM, SnyderM, JonesS. 2007. Genome-wide profiles of STAT1 DNA association using chromatin immunoprecipitation and massively parallel sequencing. Nat Methods, 4(8):651–657.
48.
SaitoT, GaleMJr. 2008. Regulation of innate immunity against hepatitis C virus infection. Hepatol Res, 38(2):115–122.
49.
SaitoT, HiraiR, LooYM, OwenD, JohnsonCL, SinhaSC, AkiraS, FujitaT, GaleMJr. 2007. Regulation of innate antiviral defenses through a shared repressor domain in RIG-I and LGP2. Proc Natl Acad Sci U S A, 104(2):582–587.
50.
SaitoT, OwenDM, JiangF, MarcotrigianoJ, GaleMJr. 2008. Innate immunity induced by composition-dependent RIG-I recognition of hepatitis C virus RNA. Nature, 454(7203):523–527.
51.
SchogginsJW, RiceCM. 2011. Interferon-stimulated genes and their antiviral effector functions. Curr Opin Virol, 1(6):519–525.
52.
SchogginsJW, WilsonSJ, PanisM, MurphyMY, JonesCT, BieniaszP, RiceCM. 2011. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature, 472(7344):481–485.
53.
SenGC, FensterlV. 2012. Crystal structure of IFIT2 (ISG54) predicts functional properties of IFITs. Cell Res, 22(10):1407–1409.
54.
SokabeM, FraserCS. 2014. Human eukaryotic initiation factor 2 (eIF2)-GTP-Met-tRNAi ternary complex and eIF3 stabilize the 43 S preinitiation complex. J Biol Chem, 289(46):31827–31836.
55.
SumpterRJr., WangC, FoyE, LooYM, GaleMJr. 2004. Viral evolution and interferon resistance of hepatitis C virus RNA replication in a cell culture model. J Virol, 78(21):11591–11604.
56.
TatenoC, KawaseY, TobitaY, HamamuraS, OhshitaH, YokomichiH, SanadaH, KakuniM, ShiotaA, KojimaY, IshidaY, ShitaraH, WadaNA, TateishiH, SudohM, NagatsukaS, JishageK, KoharaM. 2015. Generation of novel chimeric mice with humanized livers by using hemizygous cDNA-uPA/SCID mice. PLoS One, 10(11):e0142145.
57.
ThomasDL, ThioCL, MartinMP, QiY, GeD, O'HUiginC, KiddJ, KiddK, KhakooSI, AlexanderG, GoedertJJ, KirkGD, DonfieldSM, RosenHR, ToblerLH, BuschMP, McHutchisonJG, GoldsteinDB, CarringtonM. 2009. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature, 461(7265):798-U52.
58.
ThomasE, GonzalezVD, LiQ, ModiAA, ChenW, NoureddinM, RotmanY, LiangTJ. 2012. HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons. Gastroenterology, 142(4):978–988.
59.
TillmannHL, ThompsonAJ, PatelK, WieseM, TenckhoffH, NischalkeHD, LokhnyginaY, KulligU, GobelU, CapkaE, WiegandJ, SchiefkeI, GuthoffW, GrungreiffK, KonigI, SpenglerU, McCarthyJ, ShiannaKV, GoldsteinDB, McHutchisonJG, TimmJ, NattermannJ. 2010. A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterology, 139(5):1586–1592, 1592 e1.
60.
WangCF, PflugheberJ, SumpterR, SodoraDL, HuiD, SenGC, GaleM. 2003. Alpha interferon induces distinct translational control programs to suppress hepatitis C virus RNA replication. J Virol, 77(7):3898–3912.
61.
WedemeyerH, DoreGJ, WardJW. 2015. Estimates on HCV disease burden worldwide—filling the gaps. J Viral Hepat 22 Suppl 1:1–5.
62.
YamasakiC, KataokaM, KatoY, KakuniM, UsudaS, OhzoneY, MatsudaS, AdachiY, NinomiyaS, ItamotoT, AsaharaT, YoshizatoK, TatenoC. 2010. In vitro evaluation of cytochrome P450 and glucuronidation activities in hepatocytes isolated from liver-humanized mice. Drug Metab Pharmacokinet, 25(6):539–550.
63.
ZustR, Cervantes-BarraganL, HabjanM, MaierR, NeumanBW, ZiebuhrJ, SzretterKJ, BakerSC, BarchetW, DiamondMS, SiddellSG, LudewigB, ThielV. 2011. Ribose 2'-O-methylation provides a molecular signature for the distinction of self and non-self mRNA dependent on the RNA sensor Mda5. Nat Immunol, 12(2):137–143.
